Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "MeiraGTx" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about MeiraGTx for you to read. Along with our medical data and news we also list MeiraGTx Clinical Trials, which are updated daily. BioPortfolio also has a large database of MeiraGTx Companies for you to search.
Janssen, the pharmaceuticals arm of Johnson & Johnson, is once again collaborating with US clinical-stage gene therapy company MeiraGTx to develop and commercialize treatments for inherited retinal diseases (IRDs).
Janssen enters collaboration with MeiraGTx for the development and commercialization of retinal disorder gene therapies.
. @JanssenGlobal to Develop @MeiraGTx’s Retinal Disease Gene Therapies: http://ow.ly/qjDW30nwNpi pic.twitter.com/wISRWpeoS2
Janssen seals global inherited retinal disease partnership with gene therapy firm MeiraGTx http://bit.ly/2UyebwW @JanssenUK @JanssenUS #pharma #genetherapy
Janssen seals global inherited retinal disease partnership with gene therapy firm MeiraGTx http://bit.ly/2UyebwW @JanssenUK @JanssenUS #pharma pic.twitter.com/SVmtiJ8yuS
In a bid to boost its portfolio in the eye care space, Janssen has announced a global partnership with clinical-stage gene therapy firm MeiraGTx Holdings with the goal of developing and marketing new treatments for inherited retinal diseases. Specifically, the collaboration hopes to look into developing leading candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3, and X...
Licenses two inherited retinal disorder candidates
Janssen Pharmaceuticals, a Johnson & Johnson unit, and MeiraGTx have entered a worldwide licensing deal for the development, -More-
The early-stage deal is a sign of growing interest from pharma in advancing gene therapy development, analysts said.
MeiraGTx has five programs in clinical development and a pipeline of preclinical and research programs. As part of a worldwide collaboration and license agreement, the partnership will develop, The post Janssen, MeiraGTx sign $440m deal to develop gene therapy programs for IRDs appeared first on Pharmaceutical Business review.
Johnson and Johnson subsidiary Janssen has entered into a collaboration and licence agreement with gene therapy company MeiraGTx for the...Read More... The post Janssen signs inherited retinal disease therapies deal with MeiraGTx appeared first on Pharmaceutical Technology.
MeiraGTx has announced a strategic collaboration with Johnson & Johnson’s Janssen to develop and commercialise gene therapy treatments for inherited retinal diseases (IRDs).
. @JNJNews's @JanssenGlobal partners with @MeiraGTx on retinal disease #genetherapy: http://ow.ly/qjDW30nwNpi
RARITAN, N.J., Jan. 31, 2019 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc (NASDAQ: MGTX), a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leading product candidates...
MeiraGTx Holdings PLC received exclusive global rights from the National Institutes of Health’s National Institute of Denta...
MeiraGTx Holdings PLC and Janssen Pharmaceuticals Inc. are teaming up in the gene therapy space.
MeiraGTx Holdings PLC and Janssen Pharmaceuticals Inc. are teaming up in the development and commercialization of gene therap...
While it wants to keep other programs for diseases with larger patient populations in house, MeiraGTx believes J&J offers the...
. @JanssenGlobal to Develop @MeiraGTx’s Retinal Disease Gene Therapies: http://ow.ly/qjDW30nwNpi pic.twitter.com/AeJcHsNEEs
Johnson & Johnson’s Janssen Pharmaceutical Cos. will partner with MeiraGTX Holdings to develop, manufacture and commercialize its clinical-stage inherited retinal disease portfolio, the companies said today, through a global collaboration and license agreement that could generate more than $440 million for MeiraGTx. The collaboration—the second between the companies launched in the past th...
Johnson & Johnson dives deeper into gene therapy via pact with MeiraGTx https://www.firstwordpharma.com/node/1622189 $JNJ
Gene therapy has come of age over the past few years. And Johnson & Johnson this morning gave its biggest signal yet that it wants in on the emerging field. J&J (NYSE: JNJ) has inked a deal with MeiraGTX (NASDAQ: MGTX) to grab rights to a group of experimental gene therapies for inherited forms of […]
$JNJ Janssen Enters Worldwide Collaboration and License Agreement with $MGTX to Develop Gene Therapy Programs for Inherited Retinal Diseases https://www.prnewswire.com/news-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-meiragt
$JNJ Janssen Enters Worldwide Collaboration and License Agreement with $MGTX to Develop Gene Therapy Programs for Inherited Retinal Diseases https://www.prnewswire.com/news-releases/janssen-enters-worldwide-c